1-(3,5-Dimethylpyridin-2-yl)piperazine → (R)-[4-(3,5-dimethylpyridin-2-yl)piperazin-1-yl][4-(3-methyl-1,1-dioxo-1lambda6-isothiazolidin-2-ylmethyl)phenyl]methanone
반응식
[CH3:1][C@@H:2]1[CH2:6][CH2:5][S:4](=[O:8])(=[O:7])[N:3]1[CH2:9][C:10]1[CH:19]=[CH:18][C:13]([C:14]([O:16]C)=O)=[CH:12][CH:11]=1.[CH3:20][C:21]1[C:22]([N:28]2[CH2:33][CH2:32][NH:31][CH2:30][CH2:29]2)=[N:23][CH:24]=[C:25]([CH3:27])[CH:26]=1>>[CH3:20][C:21]1[C:22]([N:28]2[CH2:29][CH2:30][N:31]([C:14]([C:13]3[CH:12]=[CH:11][C:10]([CH2:9][N:3]4[C@H:2]([CH3:1])[CH2:6][CH2:5][S:4]4(=[O:7])=[O:8])=[CH:19][CH:18]=3)=[O:16])[CH2:32][CH2:33]2)=[N:23][CH:24]=[C:25]([CH3:27])[CH:26]=1참가 물질
3
실험 절차
Using methyl (R)-4-(3-methyl-1,1-dioxo-1λ6-isothiazolidin-2-ylmethyl)benzoate (79 mg) described in Preparation Example 42 and 1-(3,5-dimethylpyridin-2-yl)piperazine (53 mg) described in Preparation Example 79 and by the reaction and treatment in the same manner as in Example 109, the title compound (96 mg) was obtained.